Market LIVE
Published markets; coverage varies by country
Product profile · United States

LAMICTAL XR

 ·  Patent Litigation & Settlement History ↓

IngredientLAMOTRIGINE
Application typeNDA
Application022115
Product006
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
Strength250MG
Approval date2011-06-21
Marketing statusPrescription
Status event—
ApplicantGLAXOSMITHKLINE LLC
Product source

Current GenericRadar decision

Year2012
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2012-12-26
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2012-12-26
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
86375122029-01-07DP ————
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
201374 / 005FINAL_APPROVAL · FINAL_APPROVED2012-12-26—PH HEALTH LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
201791 / 005FINAL_APPROVAL · FINAL_APPROVED2013-01-18—PH HEALTH LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
200672 / 006FINAL_APPROVAL · FINAL_APPROVED2013-11-13—ACTAVIS ELIZABETH LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
202383 / 006FINAL_APPROVAL · FINAL_APPROVED2018-09-06—DR REDDYS LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
207497 / 005FINAL_APPROVAL · FINAL_APPROVED2018-11-30—AMNEAL PHARMACEUTICALS OF NEW YORK LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
207763 / 005FINAL_APPROVAL · FINAL_APPROVED2020-04-01—ZYDUS PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213949 / 005FINAL_APPROVAL · FINAL_APPROVED2021-12-08—YILING PHARMACEUTICAL LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211821 / 002FINAL_APPROVAL · FINAL_APPROVED2024-10-01—ALEMBIC PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 8 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
201374 / 005PH HEALTH LTDFINAL_APPROVAL · FINAL_APPROVED2012-12-26 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
201791 / 005PH HEALTH LTDFINAL_APPROVAL · FINAL_APPROVED2013-01-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
200672 / 006ACTAVIS ELIZABETH LLCFINAL_APPROVAL · FINAL_APPROVED2013-11-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
202383 / 006DR REDDYS LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2018-09-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
207497 / 005AMNEAL PHARMACEUTICALS OF NEW YORK LLCFINAL_APPROVAL · FINAL_APPROVED2018-11-30 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
207763 / 005ZYDUS PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2020-04-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213949 / 005YILING PHARMACEUTICAL LTDFINAL_APPROVAL · FINAL_APPROVED2021-12-08 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211821 / 002ALEMBIC PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2024-10-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2012-12-26TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.